Vanda Pharmaceuticals Launches NEREUS (Tradipitant) - First New Motion Sickness Drug in 40+ Years Now Available

Key Takeaways

• NEREUS (tradipitant) is the first new FDA-approved prescription motion sickness medication in more than 40 years
• The drug is available nationwide through a direct-to-consumer platform at nereus.us for preventing motion-induced vomiting in adults
• This launch represents a significant advancement for the estimated 25-40% of people who suffer from motion sickness

---

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) announced today that NEREUS™ (tradipitant) is now commercially available across the United States, representing a breakthrough in motion sickness treatment after four decades without new prescription options.

The drug is approved for preventing vomiting induced by motion in adults and can be ordered directly through the company’s consumer platform at nereus.us, eliminating traditional pharmacy visits for this condition.

Market Impact and Patient Need

Motion sickness affects an estimated 25-40% of the general population, with symptoms ranging from mild nausea to severe vomiting during travel by car, boat, plane, or other forms of transportation. Current treatment options have remained largely unchanged since the 1980s, consisting primarily of antihistamines like dimenhydrinate (Dramamine) and scopolamine patches.

Tradipitant represents a novel approach as a neurokinin-1 (NK1) receptor antagonist, targeting different pathways in the brain compared to existing treatments. This mechanism may offer improved efficacy or reduced side effects for patients who don’t respond well to traditional antihistamines.

Direct-to-Consumer Strategy

Vanda’s decision to launch NEREUS through a direct-to-consumer model reflects growing trends in pharmaceutical distribution, particularly for conditions that may not require ongoing physician monitoring. This approach could improve patient access while potentially reducing healthcare system burden.

The commercial launch follows FDA approval earlier this year, marking a significant milestone for Vanda Pharmaceuticals, which has focused on developing treatments for neurological and psychiatric conditions.

Clinical Significance

The approval of tradipitant fills a notable gap in motion sickness therapeutics, where innovation has lagged despite the common nature of the condition. For frequent travelers, transportation workers, and others regularly affected by motion sickness, NEREUS may provide a new option when existing treatments prove inadequate.

The drug’s availability nationwide positions Vanda to capture market share in the motion sickness treatment space, though pricing and insurance coverage details have not been disclosed.

---

Frequently Asked Questions

How can patients get NEREUS (tradipitant)?

NEREUS is available through a direct-to-consumer platform at nereus.us, allowing patients to order the prescription medication online without visiting traditional pharmacies.

How does NEREUS differ from existing motion sickness treatments?

NEREUS (tradipitant) works as an NK1 receptor antagonist, targeting different brain pathways than traditional antihistamine-based treatments like Dramamine or scopolamine patches.

Who can use NEREUS for motion sickness?

NEREUS is FDA-approved for preventing motion-induced vomiting in adults. Patients should consult healthcare providers to determine if it’s appropriate for their specific situation.